1. Comparison of [ 18 F]FIMP, [ 11 C]MET, and [ 18 F]FDG PET for early-phase assessment of radiotherapy response.
- Author
-
Nozaki S, Nakatani Y, Mawatari A, Shibata N, Hume WE, Hayashinaka E, Wada Y, Doi H, and Watanabe Y
- Subjects
- Cell Line, Tumor, Radiopharmaceuticals, Carbon Radioisotopes, Fluorodeoxyglucose F18, Positron-Emission Tomography
- Abstract
Several limitations of [
18 F]FDG have been reported, such as nonspecific uptake of inflammation foci. Moreover, [11 C]MET has been found to accumulate in normal and inflammatory tissues as well as tumors. To increase specificity to tumor tissues, PET probes with tumor-specific molecular targets have been actively developed. [18 F]FIMP was found to be highly accumulated in LAT1-positive tumors but not in inflamed tissue. The aim of this study was to explore whether [18 F]FIMP can be used for the early-phase evaluation of radiotherapy accompanied by inflammation, and compare its effectiveness with those of [11 C]MET and [18 F]FDG. Tumor uptake of [18 F]FIMP decreased at day 1 after irradiation, and remained low until day 14. Comparatively, that of [18 F]FDG initially decreased at day 3 but was transiently elevated at day 7 and then decreased again at day 10. Decreased tumor uptake of [11 C]MET was observed at day 10. In line with the uptake of [18 F]FIMP, the ratio of Ki-67 immuno-positive cells in tumor tissues significantly decreased at day 1, 7, and 10 as compared with that in the control. These findings suggest that [18 F]FIMP may be a PET probe involved in the early detection and prediction of radiotherapy efficacy, although further clarification is needed., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF